Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

被引：101

作者：

Lokhorst, Henk M. ^{[1
]}

Schmidt-Wolf, Ingo ^{[2
]}

Sonneveld, Pieter ^{[1
]}

van der Holt, Bronno ^{[1
]}

Martin, Hans ^{[2
]}

Barge, Rene ^{[1
]}

Bertsch, Uta ^{[2
]}

Schlenzka, Jana ^{[2
]}

Bos, Gerard M. J. ^{[1
]}

Croockewit, Sandra ^{[1
]}

Zweegman, Sonja ^{[1
]}

Breitkreutz, Iris ^{[2
]}

Joosten, Peter ^{[1
]}

Scheid, Christof ^{[2
]}

van Marwijk-Kooy, Marinus ^{[1
]}

Salwender, Hans-Juergen ^{[2
]}

van Oers, Marinus H. J. ^{[1
]}

Schaafsma, Ron ^{[1
]}

Naumann, Ralph ^{[2
]}

Sinnige, Harm ^{[1
]}

Blau, Igor ^{[2
]}

Delforge, Michel ^{[1
]}

de Weerdt, Okke ^{[1
]}

Wijermans, Pierre ^{[1
]}

Wittebol, Shulamiet ^{[1
]}

Duersen, Ulrich ^{[2
]}

Vellenga, Edo ^{[1
]}

Goldschmidt, Hartmut ^{[2
]}

机构：

[1] Dutch Belgian Hematooncol Cooperat Grp HOVON, Amsterdam, Netherlands

[2] German GMMG, Heidelberg, Germany

来源：

HAEMATOLOGICA | 2007年 / 93卷 / 01期

关键词：

thalidomide; untreated multiple myeloma;

D O I：

10.3324/haematol.11644

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the prospective phase 3 HOVON-50/GMMG-1-1D3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher afterTAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

引用

页码：124 / 127

页数：4

共 20 条

[11] Stem-cell transplantation in multiple myeloma [J].

Harousseau, JL ;

Moreau, P ;

Attal, M ;

Facon, T ;

Avet-Loiseau, H .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :603-618

[12] Role of VAD in the initial treatment of multiple myeloma [J].

Lane, SW ;

Gill, D ;

Mollee, PN .

BLOOD, 2005, 106 (10) :3674-3674

[13] Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [J].

Minnema, MC ;

Breitkreutz, I ;

Auwerda, JJA ;

van der Holt, B ;

Cremer, FW ;

van Marion, AMW ;

Westveer, PHM ;

Sonneveld, P ;

Goldschmidt, H ;

Lokhorst, HM .

LEUKEMIA, 2004, 18 (12) :2044-2046

[14] PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [J].

Oakervee, HE ;

Popat, R ;

Curry, N ;

Smith, P ;

Morris, C ;

Drake, M ;

Agrawal, S ;

Stec, J ;

Schenkein, D ;

Esseltine, DL ;

Cavenagh, JD .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) :755-762

[15] Effect of complete response on outcome following autologous stem cell transplantation for myeloma [J].

Rajkumar, SV ;

Fonseca, R ;

Dispenzieri, A ;

Lacy, MQ ;

Witzig, TE ;

Lust, JA ;

Larson, D ;

Therneau, TM ;

Kyle, RA ;

Litzow, MR ;

Greipp, PR ;

Gertz, MA .

BONE MARROW TRANSPLANTATION, 2000, 26 (09) :979-983

[16] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma [J].

Rajkumar, SV ;

Hayman, SR ;

Lacy, MQ ;

Dispenzieri, A ;

Geyer, SM ;

Kabat, B ;

Zeldenrust, SR ;

Kumar, S ;

Greipp, PR ;

Fonseca, R ;

Lust, JA ;

Russell, SJ ;

Kyle, RA ;

Witzig, TE ;

Gertz, MA .

BLOOD, 2005, 106 (13) :4050-4053

[17] Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma [J].

Rajkumar, SV ;

Hayman, S ;

Gertz, MA ;

Dispenzieri, A ;

Lacy, MQ ;

Greipp, PR ;

Geyer, S ;

Iturria, N ;

Fonseca, R ;

Lust, JA ;

Kyle, RA ;

Witzig, TE .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4319-4323

[18] Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study [J].

Segeren, CM ;

Sonneveld, P ;

van der Holt, B ;

Vellenga, E ;

Croockewit, AJ ;

Verhoef, GEG ;

Cornelissen, JJ ;

Schaafsma, MR ;

van Oers, MHJ ;

Wijermans, PW ;

Fibbe, WE ;

Wittebol, S ;

Schouten, HC ;

Kooy, MV ;

Biesma, DH ;

Baars, JW ;

Slater, R ;

Steijaert, MMC ;

Buijt, I ;

Lokhorst, HM .

BLOOD, 2003, 101 (06) :2144-2151

[19] Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma [J].

Segeren, CM ;

Sonneveld, P ;

van der Holt, B ;

Baars, JW ;

Biesma, DH ;

Cornellissen, JJ ;

Croockewit, AJ ;

Dekker, AW ;

Fibbe, WE ;

Löwenberg, B ;

Kooy, MV ;

van Oers, MHJ ;

Richel, DJ ;

Schouten, HC ;

Vellenga, E ;

Verhoef, GEG ;

Wijermans, PW ;

Wittebol, S ;

Lokhorst, HM .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (01) :127-130

[20] Thalidomide alone or with dexamethasone for previously untreated multiple myeloma [J].

Weber, D ;

Rankin, K ;

Gavino, M ;

Delasalle, K ;

Alexanian, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :16-19

← 1 2 →